Log In
Print
BCIQ
Print
Print this Print this
 

ALKS 5461

  Manage Alerts
Collapse Summary General Information
Company Alkermes plc
DescriptionCombination of ALKS 33, a mu opioid receptor (OPRM1; MOR) antagonist, and buprenorphine
Molecular Target Mu opioid receptor (OPRM1) (MOR) ; Kappa opioid receptor (OPRK1) (KOR)
Mechanism of ActionMu opioid receptor agonist; Kappa opioid receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationDepression
Indication DetailsTreat refractory major depressive disorder (MDD)
Regulatory Designation

U.S. - Fast Track (Treat refractory major depressive disorder (MDD))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today